Bacteriophage Therapy for Cystic Fibrosis

I'm Interested!

A Phase 1b/2, Multi-Centered, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Microbiological Activity of a Single Dose of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized with Pseudomonas aeruginosa

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I/II
Conditions Being Studied: Cystic Fibrosis (CF)

Study Purpose

This study is designed to test the safety and microbiological activity of a single dose of intravenous bacteriophage therapy in clinically stable participants with cystic fibrosis and Pseudomonas aeruginosa lung infection.

Who Can Participate

Age: 18 and above

Principal Investigator
Kimberly McBennett MD PhD

Department/Division
Pediatrics (Pulmonology)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: SITE00001504
StudyID: 2021-0614
ClinicalTrials.gov: NCT05453578

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422